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Idiopathic pulmonary fibrosis is a progressive and lethal form of interstitial lung
disease that lacks effective therapies at present. Glycyrrhizic acid (GA), a natural
compound extracted from a traditional Chinese herbal medicine Glycyrrhiza glabra,
was recently reported to benefit lung injury and liver fibrosis in animal models, yet
whether GA has a therapeutic effect on pulmonary fibrosis is unknown. In this study,
we investigated the potential therapeutic effect of GA on pulmonary fibrosis in a rat
model with bleomycin (BLM)-induced pulmonary fibrosis. The results indicated that
GA treatment remarkably ameliorated BLM-induced pulmonary fibrosis and attenuated
BLM-induced inflammation, oxidative stress, epithelial-mesenchymal transition, and
activation of transforming growth factor-beta signaling pathway in the lungs. Further,
we demonstrated that GA treatment inhibited proliferation of 3T6 fibroblast cells,
induced cell cycle arrest and promoted apoptosis in vitro, implying that GA-mediated
suppression of fibroproliferation may contribute to the anti-fibrotic effect against BLM-
induced pulmonary fibrosis. In summary, our study suggests a therapeutic potential of
GA in the treatment of pulmonary fibrosis.
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Introduction
Idiopathic pulmonary ﬁbrosis (IPF) is a progressive, usually fatal, form of interstitial lung disease
of unknown etiology. IPF is characterized by areas of peripheral ﬁbrosis, interstitial inﬂammation,
failure of alveolar re-epithelialization, persistence of ﬁbroblasts/myoﬁbroblasts, and deposition of
extracellular matrix (ECM) molecules in the lung, and it resembles the histopathological pattern
of usual interstitial pneumonitis (UIP; White et al., 2003). The progression of IPF may ultimately
result in distortion of lung architecture and respiration failure, and the estimated 5-years survival
of IPF is approximately 20% (King et al., 2001).
Fibroblasts play a critical role in the repair and regenerative process in almost all human tissues.
Following injury, clusters of ﬁbroblasts with an activated myoﬁbroblast phenotype are transiently
present in the granulation tissue, namely ﬁbroblast foci, and they represent microscopic zones
where ﬁbroblasts migrate, proliferate, and secrete ECM proteins that provide a tissue scaﬀold
for the repair process (Lorena et al., 2002). The activated ﬁbroblasts, or myoﬁbroblasts, are
intermediates between ﬁbroblasts and smooth muscle cells, simultaneously producing collagen and
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expressing α-smooth muscle actin (α-SMA; Hu and Phan, 2013),
and they are involved in the physiological wound healing process
and in the pathological ﬁbrosis (Lorena et al., 2002; Kramann
et al., 2013). Fibroblast foci have long been described in IPF
(Katzenstein and Myers, 1998), and ﬁbroblasts/myoﬁbroblasts
are recognized to be the key eﬀector cells in ﬁbrogenesis and in
the pathogenesis of IPF (White et al., 2003).
The conventional therapeutic strategies for IPF with
corticosteroids and immunomodulatory agents are based on
the paradigm that chronic inﬂammation leads to prolonged
tissue injury and ﬁbrosis. However, they are largely ineﬀective
and sometimes render prominent adverse eﬀects (Flaherty
et al., 2001; Spagnolo et al., 2015). Hence, searching for novel
therapeutic agents with high eﬃcacy and low toxicity is critical
to manage disease progression and ultimately cure the patients
with IPF.
Glycyrrhizic acid (GA), which is extracted from a traditional
Chinese herbal medicine Glycyrrhiza glabra, is a major active
component in G. glabra and has been demonstrated by
modern scientiﬁc approaches to possess a wide spectrum of
pharmaceutical properties, such as anti-inﬂammatory, anti-
diabetic, anti-oxidant, anti-tumor, anti-microbial, and anti-viral
properties (Ploeger et al., 2001; Ming and Yin, 2013). GA and
derivatives have been shown to exert beneﬁcial eﬀects in the
lungs against chemical-induced acute lung injury in animal
models by modulating the expression and activity of several
redox enzymes (Ni et al., 2011; Qamar et al., 2012). Moreover,
GA can alleviate asthma in ovalbumin-sensitized mice via the
immunoregulatory eﬀects on T cells (Ma et al., 2013). Recently,
GA was implicated to inhibit CCl4-induced liver ﬁbrosis in rats
(Guo et al., 2013; Liang et al., 2015), suggesting a protective eﬀect
of GA against progressive ﬁbrosis after tissue injury. Yet, whether
GA has a protective eﬀect against pulmonary ﬁbrosis remains
unclear.
This study aimed to investigate the potential therapeutic
eﬀect of GA for IPF using a rat model with bleomycin
(BLM)-induced pulmonary ﬁbrosis. The results demonstrated
that GA treatment signiﬁcantly ameliorated BLM-induced
pulmonary ﬁbrosis, inﬂammation, oxidative stress, epithelial-
mesenchymal transition (EMT) and activation of transforming
growth factor-beta (TGF-β) signaling pathway in the lungs.
Furthermore, the in vitro study revealed that GA could suppress
proliferation, promote apoptosis and inhibit migration of
ﬁbroblast cells.
Materials and Methods
Establishment of BLM-induced Pulmonary
Fibrosis in Rats and GA Treatment
Forty male 8-weeks-old Sprague-Dawley rats, weighing around
250 g, were used in this study. The rats were hosted in compliance
with the international guidelines of laboratory animal care, and
the procedures on animals were approved by the Institutional
Animal Care and Use Committee of Dalian Medical University.
The rats were randomly divided into ﬁve groups with eight
rats in each group: control, BLM, BLM+GA50, BLM+GA100,
and BLM+GA200. Induction of pulmonary ﬁbrosis with BLM
was conducted according to a previously described method
(Thrall et al., 1979). All rats were anesthetized with 10% hydrate
chloride (Sinopharm, Shanghai, China) at 3.5 ml/kg body weight
(bw). Following anesthesia, a midline cut of the neck skin
was made, and the trachea was exposed by blunt dissection.
The needle of 1 ml syringe was inserted into the trachea, and
bleomycin (Melonepharma, Dalian, China), dissolved in 100 μl
sterile saline, was injected into the rat’s lungs at a dose of
5 mg/kg bw, while an equal volume of saline was injected
into the rats from the Control group. The rats were rotated
immediately after injection to ensure an even distribution of
BLM in the lungs, and then the neck skin incision was sewn.
Thereafter, the rats from the BLM+GA50, BLM+GA100, and
BLM+GA200 groups received an intraperitoneal injection of
GA at a dose of 50, 100, and 200 mg/kg bw respectively
every day for a total of 28 days, and the rest animals received
saline. The rats were sacriﬁced 28 days after BLM induction,
the bronchoalveolar lavage ﬂuids (BALFs) were collected by
intratracheal instillation and draining of 1.5 ml saline for
three times, and then the lungs were excised for further
analysis.
Histopathological Examination
The lungs were ﬁxed, paraﬃn embedded, sectioned at 5 μm
and stained with hematoxylin and eosine (H&E; Solarbio,
Beijing, China) for microscopic examination of morphological
changes. The sections were also subjected to Masson staining
to identify collagen ﬁbers. Brieﬂy, the sections were incubated
with hematoxylin for 6 min to stain the nuclei and then with
Ponceau-Fuchsin acid solution (0.7% w/v ponceau, 0.3% w/v
fuchsin acid, 1% v/v glacial acetic acid, all from Sinopharm,
Shanghai, China) for 1 min to stain the cytoplasm. After washing
with 0.2% glacial acetic acid, the sections were incubated with
1% phosphomolybdic acid for 5 min to destain the connective
tissue, and the collagen ﬁbers were stained by aniline blue (2%
w/v aniline blue + 2% v/v glacial acetic acid) for 5 min. The
sections were dehydrated, mounted, and observed at 200 ×
magniﬁcation.
Lung Index Assay
A fraction of the lung was cut oﬀ and weighed prior to and
following drying in an incubator at 60◦C for 72 h. The pulmonary
edema was calculated as the wet/dry (W/D) weight ratio.
Determination of Collagen I and
Hydroxyproline Levels in the Lung
To determine the content of collagen I in the lungs, exactly 50 mg
lung tissue was physically homogenized in PBS and subjected
to freezing-thaw in liquid nitrogen for three times. The level of
collagen I in the tissue homogenate was determined with the
Collagen Type I Alpha 2 ELISA (enzyme-linked immunosorbent
assay) Kit (Cat. No.: SEA571Ra, USCN,Wuhan, China) following
the manufacturer’s instructions. The tissue homogenates were
centrifuged and the supernatant was collected. The protein
concentration in the supernatant was determined with the BCA
Assay Kit (Beyotime, Haimen, China), and 0.5 mg protein sample
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was used to measure the content of hydroxyproline using the
Hydroxyproline Assay Kit (Cat. No.: A030-1, Jiancheng, Nanjing,
China) according to the manufacturer’s instructions.
Differential Cell Count in BALF
The BALF was centrifuged at 1,000 g for 10 min at 4◦C, and the
supernatant was stored immediately at−80◦C until analysis. The
cell pellet was resuspended in 0.5 ml PBS, and 10 μl of the cell
suspension was made into the smear on a glass slide. The cell
smear was air-dried, ﬁxed in methanol for 15 min, and stained
with Giemsa solution (Jiancheng). The total and diﬀerential
leukocyte counts were determined under 400× magniﬁcation.
BALF Biochemical Analysis
The levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-
1β, and IL-6 in BALF were determined by ELISA using the
commercially available kits (Cat. No.: SEA133Ra, SEA563Ra,
and SEA079Ra, USCN) in accordance with the manufacturer’s
instructions.
Determination of the Level of MDA and the
Activity of MPO in the Lung
Lung tissue homogenates were subjected to the assay of
myeloperoxidase (MPO) activity using the MPO Assay Kit
(Cat. No.: A044, Jiancheng) according to the manufacturer’s
instructions. The lung homogenates were centrifuged and the
supernatant was collected. The protein concentration in the
supernatant was determined with the BCA Assay Kit, and
the level of malondialdehyde (MDA) was determined with the
MDA Assay Kit (Cat. No.: A003-1, Jiancheng) following the
manufacturer’s instructions.
Immunofluorescence Staining
The lung sections were dewaxed, heated in the antigen retrieval
reagent (18 mM citric acid and 82 mM sodium citrate) for
10 min and blocked with goat serum (Solarbio). The sections
were incubated with anti-E-cadherin antibody (1:100, Cat. No.:
BA0474, Boster, Wuhan, China) overnight at 4◦C, followed by
incubation with Cy3-conjugated goat anti-rabbit IgG antibody
(1:200, Cat. No.: A0516, Beyotime) for 1 h at room temperature.
Thereafter, the cell nuclei were brieﬂy stained with DAPI
(Biosharp, Korea). The sections were washed, mounted and
observed under a BX53 ﬂuorescence microscope (Olympus,
Japan).
Immunoblotting
For total protein extraction, lung tissues were physically
homogenized and lysed with RIPA lysis buﬀer containing 1% v/v
PMSF (Beyotime), and the cultured cells were lysed with NP-40
lysis buﬀer (Beyotime). Protein concentration was determined
with the BCA Assay Kit. A total of 40 μg proteins from each
sample were separated by SDS-PAGE, and then transferred
onto PVDF membranes (Millipore, Bedford, MA, USA). The
membranes were blocked with 5% non-fat milk and incubated
with a speciﬁc primary antibody against the protein of interest
overnight at 4◦C. Anti-TGF-β1 (Cat. No.: sc-146), anti-Cyclin B1
(Cat. No.: sc-245), and anti-P53 (Cat. No.: sc-6243) antibodies
were purchased from Santa Cruz (Dallas, TX, USA); anti-
Smad2 (Cat. No.: bs-0718R), anti-p-Smad2 (Cat. No.: bs-5618R),
anti-Smad3 (Cat. No.: bs-3484R), anti-p-Smad3 (Cat. No.: bs-
5459R), and anti-Vimentin (Cat. No.: bs-8533R) antibodies were
from Bioss (Beijing, China); anti-E-cadherin (Cat. No.: BA0474),
anti-Fibronectin (Cat. No.: BA1772), anti-α-SMA (Cat. No.:
BM0002), anti-Cyclin D1 (Cat. No.: BM0771), anti-Cyclin E
(Cat. No.: BA0774), anti-P21 (Cat. No.: BA0272), anti-Bcl-2
(Cat. No.: BA0412), anti-MMP-3 (Cat. No.: BA1531), anti-
MMP-7 (Cat. No.: PB0071), anti-MMP-8 (Cat. No.: BA2201),
and anti-MMP-9 (Cat. No.: BA2202) antibodies were purchased
from Boster; anti-cleaved caspase-3 (Cat. No.: ab2302) and
anti-PARP (Cat. No.: ab32561) antibodies were from abcam
(Cambridge, MA, USA); antibodies against cleaved caspase-8
(WL0153) and cleaved caspase-9 (WL01551) were purchased
from Wanleibio (Shenyang, China). After incubation with
the primary antibody, the membranes were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-mouse or
goat anti-rabbit IgG secondary antibody (Beyotime) at room
temperature for 45 min, followed by signal visualization using
the enhanced chemiluminescence (ECL) system (7Sea Biotech,
Shanghai, China). The membranes were stripped with the
stripping buﬀer (Beyotime) and re-probed with anti-β-actin
antibody (Cat. No.: sc-47778, Santa Cruz) to verify equal loading
and transfer. The blot ﬁlms were scanned and analyzed with Gel-
Pro-Analyzer software to quantify the densitometric values of the
target bands.
Cell Culture and Treatment
Murine ﬁbroblast cell line 3T6 was purchased from the Cell Bank
of China Academy of Sciences (Shanghai, China). The cells were
cultured in DMEM (Gibco, Carlsbad, CA, USA) supplemented
with 10% FBS (Hyclone, Logan, UT, USA) at 37◦C in a humidiﬁed
atmosphere of 95% air and 5% CO2.
GA was dissolved in DMSO to make 180 mM concentrated
stocks, which were diluted with PBS to make the 9 mM working
solution. 3T6 cells were treated with 5, 10, 25, 50, 100, and
200 μM GA for 24 h, and the cytotoxicity was then analyzed
by measuring the activity of lactate dehydrogenase (LDH) in the
conditioned culture medium using the LDH Activity Assay Kit
(Cat. No.: A020-2, Jiancheng). Low (25 μM), medium (50 μM),
and high (100 μM) doses of GA were selected to treat the cells in
later experiments.
Proliferation Assay
Cell proliferation was assessed by the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 3T6 cells were
seeded in 96-well microplates at a density of 3,000 cells per well
and cultured at 37◦C for 24 h. GAwas added into each well to the
indicated ﬁnal concentration (0, 25, 50, or 100 μM). After 24 or
48 h GA treatment, MTT (Sigma-Aldrich, St. Louis, MO, USA)
was added into the culture medium to a ﬁnal concentration of
0.2 mg/ml for 4 h incubation at 37◦C. Thereafter, themediumwas
aspirated and the formazan crystals were dissolved completely in
200 μl DMSO per well. The optical density (OD) at 490 nm was
recorded by an ELX-800 microplate reader (BioTek, Winooski,
VT, USA). Each assay point was done in ﬁve replicates.
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FIGURE 1 | Glycyrrhizic acid (GA) alleviated BLM-induced pulmonary fibrosis in rats. Pulmonary fibrosis was induced by intratracheal instillation of BLM, and
the rats received various doses of GA by intraperitoneal injection for 28 days (n = 8 per group). (A) Histomorphological examination (200 × magnification) of the lung
sections following H&E staining. Scale bars = 100 μm. The arrows point at typical areas of fibrosis, manifesting as clusters of cells with protruding cytoplasm, i.e.,
the fibroblasts. (B) Masson’s staining of collagen (blue) in the lungs (200 × magnification). Scale bars = 100 μm. The arrows point at typical areas of fibrosis
enriched in fibroblasts and collagen fibers. (C,D) The levels of collagen I and hydroxyproline in the lungs determined by ELISA. (E) Wet/dry weight ratio of the lungs.
This figure shows the representative images from each group, and the results are expressed as the mean ± standard deviation. Compared with the control group,
∗∗p < 0.01, ∗∗∗p < 0.001; compared with the BLM group, #p < 0.05, ##p < 0.01,###p < 0.001.
TABLE 1 | Effect of GA on BLM-induced changes in total and differential cell counts in the bronchoalveolar lavage fluid of rats.
Group Total cells (×105) Neutrophils (×104) Macrophages (×105) Lymphocytes (×104)
Control 2.55 ± 0.72 4.93 ± 1.66 1.69 ± 0.52 3.69 ± 1.62
BLM 11.0 ± 1.74∗∗∗ 12.2 ± 3.63∗∗∗ 8.84 ± 1.46∗∗∗ 9.82 ± 2.76∗∗∗
BLM+GA50 9.05 ± 2.38 9.4 ± 3.36 7.27 ± 1.87 8.4 ± 3.04
BLM+GA100 6.66 ± 1.91## 8.52 ± 2.32 5.16 ± 1.57### 6.5 ± 1.97
BLM+GA200 5.42 ± 1.13### 7.13 ± 1.81# 4.16 ± 0.94### 5.45 ± 1.06#
Data are expressed as the mean ± standard deviation (n = 8 per group); Compared with the control group, ∗∗∗p < 0.001. Compared with the BLM group,
#p < 0.05,##p < 0.01, ###p < 0.001. GA, glycyrrhizic acid; BLM, bleomycin.
Flow Cytometric Analysis of Cell Cycle and
Apoptosis
Following GA treatment for 24 h, the cells were analyzed for cell
cycle and apoptosis by ﬂow cytometry. For cell cycle analysis, the
cells were harvested, ﬁxed in 70% ethanol at 4◦C for 2 h, and
incubated with the propidium iodide (PI) solution (Beyotime) for
30 min at 37◦C in the dark, followed by analysis in FACSCalibur
ﬂow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Cell
apoptosis was assayed with the Annexin V-FITC/PI Apoptosis
Detection Kit (Cat. No.: KGA106, KeyGen, Nanjing, China)
according to the manufacturer’s instructions. Following staining,
the apoptotic status of the cells was analyzed by ﬂow cytometry.
Scratch Wound Assay
Cell migration was assessed by the well-established in vitro
scratch wound assay (Liang et al., 2007). The conﬂuent
monolayer of 3T6 cells was incubated with 5 μM mitomycin-
C (Sigma-aldrich) for 2 h to inhibit cell proliferation. A scratch
was evenly created by horizontally crossing the surface of the
cell monolayer with a 200 μl pipette tip. The detached cells were
washed oﬀ with serum-free medium, and the cells were cultured
with serum-free medium containing the indicated concentration
of GA for 24 h at 37◦C in a 5% CO2 incubator. The cells were
photographed under an inverted microscope at 0, 6, 12, and 24 h
post-scratching, and the rate of wound closure was calculated
as (original gap distance - gap distance at the indicated time
point)/original gap distance × 100%.
Transwell Assay
3T6 cells were pre-treated with 5 μM mitomycin-C for 2 h,
and resuspended in culture medium containing the indicated
concentration of GA. 2 × 104 cells in 200 μl suspension were
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FIGURE 2 | Glycyrrhizic acid reduced BLM-induced elevation of inflammatory cytokines and oxidative stress in the lungs. BALF was collected after the
rats were sacrificed. (A) The total protein level in the BALF was determined by the BCA assay kit. (B–D) The levels of TNF-α, IL-1β and IL-6 in the BALF were
assayed by ELISA. (E) The MDA content and (F) the MPO activity in the lungs were examined by the respective kits. The results are presented as the
mean ± standard deviation (n = 8 per group). Compared with the control group, ∗∗∗p < 0.001; compared with the BLM group, ##p < 0.01,###p < 0.001.
plated in one Transwell chamber (Corning) pre-coated with
Matrigel (BD Biosciences). The Transwell chamber was then
placed into a 24-well plate with each well-containing 800 μl
culture medium supplemented with 20% FBS. The cells were
cultured for 24 h at 37◦C in an atmosphere of 5%CO2. Thereafter,
the cells and the Matrigel on the top surface of the Transwell
membrane were wiped oﬀ, and the cells on the bottom surface
of the membrane were ﬁxed with paraformaldehyde and stained
with crystal violet (Amresco, Solon, OH, USA). The cells were
observed under a 200× inverted microscope, and the numbers of
the invading cells were counted in ﬁve ﬁelds on each membrane.
Statistical Analysis
Data were processed with the GraphPad PRISM software
(version 5.0; San Diego, CA, USA), and are presented as the
mean ± standard deviation (SD). One way analysis of variance
(ANOVA) was used to compare diﬀerences among multiple
groups, followed by Bonferroni post hoc test for comparisons
between two groups. The diﬀerences are considered statistically
signiﬁcant when p< 0.05.
Results
GA Attenuated BLM-induced Pulmonary
Fibrosis in Rats
Pulmonary ﬁbrosis was primarily assessed by the
histomorphological examination following H&E staining of the
lung sections. Twenty-eight days after intratracheal instillation
of BLM, marked thickening in alveolar septa, collapse of alveolar
spaces, loss of alveolar structure, and over-proliferation of
ﬁbroblasts were observed in the lungs from the BLM group
(Figure 1A), indicating a severe pulmonary ﬁbrosis induced by
BLM. GA treatment at a dose of 50 mg/kg bw/d (GA50) slightly
alleviated BLM-induced pathological changes in the lungs, while
higher doses of GA (GA100 and GA200) signiﬁcantly ameliorated
BLM-induced pulmonary ﬁbrosis. Local ﬁbrotic lesions were
detected in the lungs from the BLM+GA100 group, and GA at a
dose of 200 mg/kg bw/d (GA200) greatly maintained the alveolar
structure after BLM administration with mild thickening of
the lung interstitium. In addition to H&E staining, pulmonary
ﬁbrosis was veriﬁed by Masson’s staining of collagen. As shown
in Figure 1B, the area of collagen deposition spread throughout
the entire lung of the rats treated with BLM, whereas GA100 and
GA200 remarkably reduced the areas of collagen deposition after
BLM treatment. Moreover, collagen accumulation was quantiﬁed
by measuring the contents of collagen I and hydroxyproline in
the lung (Figures 1C,D). BLM treatment resulted in prominent
elevation in the levels of collagen I and hydroxyproline in the
lungs as compared with the control lungs (p < 0.001). Such
elevation was signiﬁcantly reduced by GA treatment in a dose-
dependent manner (p < 0.05, p < 0.001). Since the thickening
of the lung interstitum may also due to extra ﬂuid (edema;
Dongaonkar et al., 2009), the wet/dry weight ratio of the lung
tissues was determined. The results revealed that BLM-induced
pulmonary edema was alleviated by GA treatment, and the eﬀect
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FIGURE 3 | Glycyrrhizic acid inhibited EMT and activation of TGF-β signaling in BLM-induced pulmonary fibrosis. (A) Immunofluorescence staining of
E-cadherin (E-cad) in the lungs. The sections were photographed at 400× magnification (scale bars = 50 μm). A small window is enlarged by five times to present
the subcellular location of E-cad. (B) Immunoblotting for the epithelial marker (E-cad), myofibroblasts maker (α-SMA), and ECM molecules (Fibronectin and Vimenin)
in the lung tissues. (C) Densitometric analysis of proteins of interest in the immunoblots using β-actin as the internal reference. Values are expressed as the
mean ± standard deviation (n = 8 per group). Compared with the Control group, ∗∗p < 0.01, ∗∗∗p < 0.001; Compared with the BLM group, #p < 0.05, ##p < 0.01,
###p < 0.001. (D) Immunoblotting for TGF-β1 and its downstream signaling molecules (p-Smad2 and p-Smad3) in the lung tissues. (E) Densitometric analysis of
target proteins in (D) using β-actin as the internal reference. Values are expressed as the mean ± standard deviation (n = 8 per group). Compared with the Control
group, ∗∗∗p < 0.001; Compared with the BLM group, ##p < 0.01, ###p < 0.001.
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FIGURE 4 | Glycyrrhizic acid suppressed proliferation of 3T6 fibroblast
cells. (A) Murine fibroblast cell line 3T6 was treated with various
concentrations of GA for 24 h, and the cytotoxicity of GA was detected by the
LDH activity in the conditioned culture medium. (B) The proliferation of 3T6
cells was assessed by MTT assay after 24 and 48 h GA treatment. The results
are presented as the mean ± standard deviation of three independent
experiments. Compared with the untreated cells, ∗∗p < 0.01, ∗∗∗p < 0.001.
of GAwas dose dependent (Figure 1E). Collectively, these results
indicated that GA could ameliorate BLM-induced pulmonary
ﬁbrosis in a dose-dependent manner.
GA Mitigated Inflammation and Oxidative
Stress in BLM-induced Pulmonary Fibrosis
To determine the eﬀect of GA on BLM-induced pulmonary
inﬂammatory responses in rats, the total and diﬀerential counts
of leukocytes in BALF were ﬁrstly determined. Compared
with the control rats, a signiﬁcant inﬂux of inﬂammatory
cells was observed in the BALF from the rats with BLM-
induced pulmonary ﬁbrosis, and the numbers of neutrophils,
macrophages and lymphocytes were all increased (Table 1).
Following 28-days GA treatment, BLM-induced increases of
inﬂammatory cell counts were markedly reduced, and such
inhibitory eﬀect was dose dependent. In addition, BLM
induction resulted in elevated levels of total protein and various
inﬂammatory cytokines in the BALF such as TNF-α, IL-1β
and IL-6, which were all reduced by GA treatment in a dose
dependent manner (Figures 2A–D).
Compared with the control rats, a signiﬁcant elevation in
MDA content, an indicator of lipid peroxidation (Torun et al.,
2009), was observed in the lung tissues of the rats exposed to
BLM, whereas GA treatment at a dose of 100 and 200 mg/kg
bw/d signiﬁcantly inhibited BLM-induced elevation of MDA in
the lungs (Figure 2E). Meanwhile, the level of MPO, a marker
of neutrophil inﬂux and oxidative stress (Pitanga et al., 2014),
was increased in BLM-treated lungs, and such increase was
remarkably attenuated by GA treatment in a dose-dependent
manner (Figure 2F). Thus, these results suggest that GA could
combat oxidative stress in BLM-induced pulmonary ﬁbrosis.
GA Inhibited EMT and Activation of TGF-β
Signaling Pathway
Epithelial-mesenchymal transition is one of the well-recognized
sources of myoﬁbroblasts in pulmonary ﬁbrosis (Willis and
Borok, 2007). The epithelial marker E-cadherin, which was
expressed in the alveolar septa of normal lungs, was markedly
down-regulated in BLM-induced pulmonary ﬁbrosis, while the
expression of E-cadherin was resumed in the rats that received
medium to high dose of GA (Figure 3A). Western blot analysis
revealed that α-SMA was upregulated in BLM-treated lungs
along with the downregulation of E-cadherin, suggesting an
enhanced EMT process in BLM-induced pulmonary ﬁbrosis
(Figures 3B,C). In contrast, GA treatment inhibited BLM-
induced EMT in the lungs by increasing the expression
of E-cadherin and simultaneously suppressing the expression
of α-SMA after BLM induction. Moreover, GA treatment
decreased BLM-induced upregulation of ECM molecules such
as Fibronectin and Vimentin, which are normally secreted by
myoﬁbroblasts during ﬁbrosis (Figures 3B,C).
Transforming growth factor-β signaling is a well-known
signaling pathway that plays a critical role in EMT during
pulmonary ﬁbrosis (Willis and Borok, 2007). Hence, we
examined the activation status of TGF-β signaling pathway
in BLM-induced pulmonary ﬁbrosis with and without GA
treatment. Compared with the control lungs, the expression of
TGF-β1 was signiﬁcantly upregulated in BLM-induced lungs,
accompanied by enhanced phosphorylation of the signaling
molecules downstream of TGF-β1, including Smad2 and Smad3
(Figures 3D,E). GA treatment of medium and high doses, on
the other hand, suppressed BLM-induced upregulation of TGF-
β1 as well as decreased the elevation of p-Smad2 and p-Smad3.
These results suggest an inhibitory eﬀect of GA on BLM-induced
activation of TGF-β signaling in the lungs.
GA Suppressed Growth and Induced
Apoptosis of Fibroblasts
Proliferation of ﬁbroblasts takes place at the initial stage of
tissue repair in response to injury, and the tightly regulated
growth and apoptosis of ﬁbroblasts are critical to restore normal
tissue architecture (Lorena et al., 2002). The eﬀect of GA on
the proliferation and apoptosis of ﬁbroblasts was investigated
in vitro by employing a murine ﬁbroblast cell line 3T6. The
cytotoxicity of GA on 3T6 cells were examined by incubating
the cells with diﬀerent concentrations of GA ranging from 5
to 200 μM for 24 h, and the LDH activity assay indicated
that GA of as high as 100 μM was non-cytotoxic to 3T6 cells
(Figure 4A). Later on, the eﬀect of GA on the proliferation of
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FIGURE 5 | Glycyrrhizic acid induced cell cycle arrest of 3T6 cells. (A) 3T6 cells were treated with the indicated concentration of GA for 24 h. The cells were
fixed and stained with PI, followed by flow cytometric analysis. (B) The flow cytometric results from three independent experiments were statistically analyzed.
(C) Western blot analysis of the key cell cycle regulatory proteins in 3T6 cells after 24 h GA treatment. (D) Densitometric analysis of proteins of interest in the
immunoblots using β-actin as the internal reference. This figure shows the representative images from three independent experiments, and the data are expressed
as the mean ± standard deviation. Compared with the untreated cells, ∗p < 0.05, ∗∗∗p < 0.001.
3T6 cells was assessed by MTT assay. It was noted that GA
treatment at the doses of 50 and 100 μM led to signiﬁcant
reduction of viable cell numbers after 24 and 48 h incubation
as compared to the untreated cells, whereas 25 μM GA
displayed the inhibitory eﬀect on cell proliferation only at 48 h
(Figure 4B). We further examined the cell cycle of 3T6 cells
after 24 h treatment with GA. The results revealed that GA
of 50 and 100 μM markedly increased the numbers of cells
at G0/G1 phase and reduced the numbers of cells at S phase
(Figures 5A,B), indicating that the cell cycle was slowed down
by GA treatment. Consistently, GA of 50 and 100 μM led to
downregulated expression of a number of cell cycle regulatory
proteins such as Cyclin B1, Cyclin D1 and Cyclin E, and
upregulated the G1 check-point proteins including P53 and P21
(Figures 5C,D). In addition, GA inhibited cell cycle and altered
the expression of the cell cycle players in a dose-dependent
manner.
Cell apoptosis was analyzed by ﬂow cytometry after 24 h
treatment of GA. The ratio of the cells that were stained as
Annexin V+ PI- and Annexin V+ PI+, representing early and
late apoptotic cells, was statistically analyzed, and the results
indicated that GA enhanced apoptosis of 3T6 cells in a dose-
dependent manner (Figures 6A,B). Further, Western blot results
showed that the levels of cleaved caspase-3, cleaved caspase-
9 and cleaved PARP, the executors of apoptotic events, were
markedly increased by GA, while the level of cleaved caspase-
9 was elevated to a less extent (Figures 6C,D). Moreover,
GA treatment resulted in downregulation of the anti-apoptotic
protein Bcl-2 and upregulation of the pro-apoptotic protein Bax
(Figures 6C,D). Thus, the altered levels of the critical apoptotic
players favored the apoptotic phenotype of 3T6 cells after GA
treatment.
GA Inhibited Migration and Invasion of 3T6
Cells
In vitro scratch wound assay and Transwell assay were performed
to assess the migration and invasion of 3T6 cells after GA
treatment. As shown in Figures 7A,B, the migration rate of
3T6 cells was signiﬁcantly reduced by GA at 50 and 100 μM
since 6 h of the assay. Notably, the invasiveness of 3T6 cells was
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FIGURE 6 | Glycyrrhizic acid promoted apoptosis of 3T6 cell. (A) Following 24 h GA treatment, 3T6 cells were double-stained with Annexin-V-FITC and PI, and
then analyzed by flow cytometry. (B) The ratio of apoptotic cells (Annexin V+ PI- and Annexin V+ PI+) was statistically analyzed. (C) Western blot analysis of several
key apoptosis regulatory proteins in 3T6 cells after 24 h GA treatment. (D) Densitometric analysis of proteins of interest in (C) using β-actin as the internal reference.
(A,C) Shows the representative images from three independent experiments. The values are expressed as the mean ± standard deviation. Compared with the
untreated cells, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.
strongly inhibited during 24 h incubation with 50 or 100 μMGA
(Figures 7C,D). Thus, these results demonstrated that GA at the
concentration of 50 or 100μMsigniﬁcantly suppressedmigration
and invasion of 3T6 cells.
Matrix metalloproteinases (MMPs) are endopeptidases
enzymes capable of degrading ECM components during cell
invasion, and they have been implicated in the pathology of
pulmonary ﬁbrosis (Craig et al., 2015). Here, we show that
treatment with GA led to dose-dependent downregulation of
MMP-3, MMP-7, MMP-8, and MMP-9 proteins in 3T6 cells
(Figures 7E,F), suggesting that GA may inhibit cell invasion by
interfering with the expression of these MMPs.
Discussion
Intratracheal administration of BLM is one of the most
extensively used experimental models in the studies of pulmonary
ﬁbrosis at present. BLM is known to stimulate inﬂammatory
responses in the lung tissues with increased inﬁltration of
leukocytes such as macrophages, granulocytes, and lymphocytes.
These inﬂammatory cells stimulate the proliferation of ﬁbroblasts
and the activation of myoﬁbroblasts which secrete ECM
components into the alveolar interstitial space, gradually
resulting in pulmonary ﬁbrosis (Mouratis and Aidinis, 2011). In
our study, intratracheal administration of BLM led to the typical
phenotypes of BLM-induced pulmonary ﬁbrosis, including
marked inﬁltration of inﬂammatory cells into the lung tissues,
elevation of inﬂammatory cytokines, excessive proliferation of
ﬁbroblasts, massive production of collagen ﬁbers, and deposition
of ECM molecules in the lungs. These pathological alterations
were all signiﬁcantly alleviated by intraperitoneal injection of GA
at 100 and 200 mg/kg bw/d for 28 days, and the therapeutic eﬀect
of GA on pulmonary ﬁbrosis was dose dependent. Hence, our
results suggest a potential value of GA in the treatment of IPF.
Idiopathic pulmonary ﬁbrosis is a heterogeneous pulmonary
disorder of undeﬁned etiology. Dysregulated ﬁbroproliferation
in response to alveolar epithelial injury has drawn extensive
attention in recent years, and current understanding of the
pathogenesis of IPF is shifting from the conventional concept
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FIGURE 7 | Glycyrrhizic acid inhibited migration and invasion of 3T6 cells. (A) The effect of GA on cell migration was assessed by scratch wound assay. The
wound closure was photographed at post-scratching 6, 12, and 24 h. (B) The wound closure rate, representing the migration rate, was measured. (C) Transwell
assay was performed to evaluate the effect of GA on the invasiveness of 3T6 cells. The cells that migrated through the membrane were stained and photographed.
(D) The number of invading cells in the Transwell assay was statistically analyzed. (E) Immunoblotting for the MMP family proteins in 3T6 cells after treatment with
various concentrations of GA. (F) Densitometric analysis of MMPs in the immunoblots using β-actin as the internal reference. (A,C,E) present the representative
images from three independent experiments, and the values are expressed as the mean ± standard deviation. Compared with the untreated cells, ∗p < 0.05,
∗∗p < 0.01, ∗∗∗p < 0.001.
of chronic inﬂammation toward dysregulated ﬁbroproliferation
(Ryu et al., 2014). In this study, we demonstrated that GA
inhibited the proliferation of 3T6 ﬁbroblasts by upregulating
the cell cycle checkpoint proteins and downregulating several
Cyclins. In addition, GA induced apoptosis of 3T6 cells via
modulating the levels of a number of key apoptosis regulatory
proteins. Particularly, GA treatment augmented the cleavage of
caspase-3 and caspase-9 to a much greater extent as compared to
GA-induced cleavage of caspase-8, suggesting that GA-stimulated
apoptosis is predominantly mediated via the intrinsic apoptotic
pathway (Bayir and Kagan, 2008). Apoptosis of ﬁbroblasts is
critical at the end of the healing process for restoration of
normal tissue architecture (Desmouliere et al., 1995). Thus, it
is likely that GA treatment inhibited proliferation and induced
apoptosis of ﬁbroblasts during the development of pulmonary
ﬁbrosis in BLM-treated rats, thus attenuating BLM-induced
ﬁbroproliferation, such as to delay the pathogenesis of pulmonary
ﬁbrosis.
TGF-β1 has been implicated in a broad spectrum of activities
in the pathogenesis of pulmonary ﬁbrosis such as pulmonary
inﬂammation (Bergeron et al., 2003), diﬀerentiation of ﬁbroblasts
into active myoﬁbroblasts and inhibition of ﬁbroblast apoptosis
(Lee et al., 2006), EMT (Willis and Borok, 2007), as well
as synthesis and deposition of collagen and ECM molecules
by myoﬁbroblasts (Ignotz and Massague, 1986). Previous
studies have demonstrated that TGF-β is the major inducer
of EMT in ﬁbrosis via Smad-dependent pathways (Li et al.,
2003). In the present study, intratracheal administration of
BLM led to increased expression of α-SMA in the lungs,
implying an increased number of myoﬁbroblasts, which may
be derived from ﬁbroblast transdiﬀerentiation or EMT. GA
treatment inhibited BLM-induced upregulation of α-SMA
and also reduced BLM-induced upregulation of TGF-β1 and
phosphorylation of Smad2/3, suggesting that GA may mitigate
BLM-induced pulmonary ﬁbrosis by inhibiting TGF-β signaling
pathway.
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Previous studies have proposed a therapeutic potential of GA
against liver ﬁbrosis (Guo et al., 2013; Liang et al., 2015). Our
study demonstrates, for the ﬁrst time, that GA can ameliorate
pulmonary ﬁbrosis in a rat model of BLM-induced pulmonary
ﬁbrosis by reducing the inﬁltration of inﬂammatory cells,
inhibiting the production of inﬂammatory cytokines, decreasing
oxidative stress and suppressing ﬁbroblast proliferation. Since
GA is known to possess anti-inﬂammatory, anti-oxidant and
anti-apoptotic properties (Guo et al., 2013; Ming and Yin, 2013;
Liang et al., 2015), the therapeutic eﬀect of GA against BLM-
induced pulmonary ﬁbrosis might be attributed to these diverse
pharmaceutical properties of GA. A previous work by Moro
et al. proposed Smad3-mediated transcription of collagen I as the
molecular mechanism for the anti-ﬁbrotic eﬀect of GA (Moro
et al., 2008). Here, we showed that GA did not only interfere with
the activation of Smad3, but also aﬀected the phosphorylation
of Smad2 and the expression of TGF-β1. Therefore, our results
suggest that GA may exert the anti-ﬁbrotic eﬀect by suppressing
the activation of TGF-β signaling pathway, probably through the
modulation of TGF-β1 expression.
The levels of most MMP family proteins are elevated in
IPF, and several MMPs have been demonstrated to promote
pulmonary ﬁbrosis in animal models mainly by upregulating
the pro-ﬁbrotic mediators, downregulating the anti-ﬁbrotic
mediators, and enhancing cell migration (Craig et al., 2015).
MMP-3 and MMP-7, in particular, have been shown to promote
the EMT process during the development of pulmonary ﬁbrosis
(Zuo et al., 2002; Yamashita et al., 2011). In this study, GA dose-
dependently reduced the expression of MMP-3, -7, -8, and -9 in
3T6 cells, suggesting that GA-induced downregulation of MMPs
may contribute to the anti-ﬁbrotic action of GA.
In the past few decades, animal models of BLM-induced
pulmonary ﬁbrosis have provided important insights in the
understanding of IPF pathogenesis. Notably, there are emerging
concerns about this model regarding the severe adverse eﬀect of
lung injury, which leads to IPF-like phenotypes but only partially
recapitulate the disease. Moreover, although a great number of
novel compounds were demonstrated to be promising based on
this model, most of them fail to show eﬃcacy in clinical trials
(Della Latta et al., 2015). Hence, in future studies, alternative
models of pulmonary ﬁbrosis may be recruited to conﬁrm the
pharmaceutical property of GA, either by chemical induction or
using transgenic animals (Wilberding et al., 2001; Moore and
Hogaboam, 2008).
Conclusion
Our study demonstrated that GA treatment signiﬁcantly
alleviated BLM-induced pulmonary ﬁbrosis in rats, providing the
preliminary evidence for the potential therapeutic value of GA
for IPF.
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